{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:01:18Z","timestamp":1780038078947,"version":"3.53.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have significantly improved survival rates in various advanced cancers, including cervical cancer. However, they can induce a range of immune-related adverse events (irAEs), with immune myocarditis being particularly dangerous, especially when combined with myositis and myasthenia gravis, forming the fatal 3M syndrome. Early symptoms are subtle, and delayed diagnosis and treatment often lead to severe consequences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 65-year-old female with stage FIGO stage IIIA cervical squamous cell carcinoma received one dose of anti-PD-1 monoclonal antibody (Enlarzumab) combined with chemoradiotherapy. Following initial disease stabilization, the patient developed early neuromuscular symptoms, including ptosis and facial weakness, on Day 21. By Day 25, she experienced sudden chest tightness and acute heart failure with new-onset atrial fibrillation and a decline in left ventricular ejection fraction from 57% to 40%. The concurrent elevation of cardiac biomarkers and creatine kinase, alongside neuromuscular involvement, confirmed the clinical diagnosis of ICI-induced 3M syndrome. Despite treatment with high-dose methylprednisolone, intravenous immunoglobulin (IVIG), and mycophenolate mofetil, the patient ultimately succumbed to progressive respiratory failure following the family\u2019s decision to decline further invasive respiratory support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights the insidious onset and rapid progression of 3M syndrome, where neuromuscular symptoms often serve as overlooked precursors to myocarditis. Establishing a systematic approach involving proactive monitoring and immediate immunosuppressive treatment is essential to ensure the safety of immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1840526","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:01:22Z","timestamp":1780034482000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Severe immune checkpoint inhibitor-induced 3M syndrome: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Hairong","family":"Yao","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, Cangzhou Central Hospital","place":["Cangzhou, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitong","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Cangzhou Central Hospital","place":["Cangzhou, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Cangzhou Central Hospital","place":["Cangzhou, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Cangzhou Central Hospital","place":["Cangzhou, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/s0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132063","article-title":"Management of triple M syndrome: A narrative review of immune checkpoint inhibitor-induced myasthenia gravis, myositis, and myocarditis","volume":"17","author":"Furlepa","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"39","author":"Weber","year":"2020","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2025.101950","article-title":"Adverse events beyond the RUBY trial: Reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case","volume":"61","author":"Abozenah","year":"2025","journal-title":"Gynecol Oncol Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jop.18.00005","article-title":"Management of immune-related adverse events in patients receiving immune checkpoint inhibitor therapy","volume":"14","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: Pathophysiology, diagnosis, and management","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis\/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases","volume":"26","author":"Pathak","year":"2021","journal-title":"The Oncologist"},{"key":"B12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11912-020-01015-1","article-title":"Immune checkpoint inhibitor-induced cardiotoxicity: current perspectives and management","volume":"23","author":"Lyon","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor\u2013Associated Myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis\u00a0and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"European Journal of Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1455347","article-title":"Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review","volume":"16","author":"Man","year":"2025","journal-title":"Front. Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4324\/9781032701004-13","article-title":"Immune checkpoint inhibitor-induced myocarditis: A systematic review and meta-analysis","volume":"80","author":"Jain","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immune Checkpoint Inhibitor-Related Adverse Events","volume":"9","author":"Brahmer","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1840526\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:01:22Z","timestamp":1780034482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1840526\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2026.1840526"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1840526","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1840526"}}